Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3CMGM5
Thu, 09.03.2023
APONTIS PHARMA AG
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded according to preliminary calculations
Single Pill revenues again grow at double-digit rate of 16% to EUR 36.5 million (2021: EUR 31.5 million)
Single Pill revenues share rises to 66% (2021: 62%)
Number of patients treated with Single Pills from AP [ … ]
Thu, 09.03.2023
APONTIS PHARMA AG
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded according to preliminary calculations
Single Pill revenues again grow at double-digit rate of 16% to EUR 36.5 million (2021: EUR 31.5 million)
Single Pill revenues share rises to 66% (2021: 62%)
Number of patients treated with Single Pills from AP [ … ]
Tue, 14.02.2023
APONTIS PHARMA AG
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023
New Single Pill for the substitution treatment of hypertension, hypertension with coexisting coronary syndrome, and/or chronic heart failure
Potential peak sales of the new Single Pill of around EUR 6 million
Market launch in [ … ]
Tue, 14.02.2023
APONTIS PHARMA AG
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing deals planned for 2023
New Single Pill for the substitution treatment of hypertension, hypertension with coexisting coronary syndrome, and/or chronic heart failure
Potential peak sales of the new Single Pill of around EUR 6 million
Market launch in [ … ]
Tue, 31.01.2023
APONTIS PHARMA AG
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill
New Single Pill with potential peak sales of approx. EUR 1.3 million
Market launch already planned for mid-2023 in Germany
Number of announced market launches increases to eleven Single Pills
Monheim am Rhein, 31 January 2023 [ … ]
Tue, 31.01.2023
APONTIS PHARMA AG
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by in-licensing a new Single Pill
New Single Pill with potential peak sales of approx. EUR 1.3 million
Market launch already planned for mid-2023 in Germany
Number of announced market launches increases to eleven Single Pills
Monheim am Rhein, 31 January 2023 [ … ]
Tue, 29.11.2022
APONTIS PHARMA AG
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
Continuous expansion of the Single Pill portfolio to meet the target of at least 20 Single Pills by 2026 – currently ten Single Pills in the portfolio
Two new drugs with potential peak sales of EUR 4.0 million
Market la [ … ]
Tue, 29.11.2022
APONTIS PHARMA AG
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
Continuous expansion of the Single Pill portfolio to meet the target of at least 20 Single Pills by 2026 – currently ten Single Pills in the portfolio
Two new drugs with potential peak sales of EUR 4.0 million
Market la [ … ]
Thu, 10.11.2022
APONTIS PHARMA AG
APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets
Superiority of Single Pill therapy confirmed in the EU-funded prospective SECURE study and fully published in the prestigious New England Journal of Medicine
Revenue from Single Pills +25.7% to EUR 27.3 million s [ … ]
Thu, 10.11.2022
APONTIS PHARMA AG
APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets
Superiority of Single Pill therapy confirmed in the EU-funded prospective SECURE study and fully published in the prestigious New England Journal of Medicine
Revenue from Single Pills +25.7% to EUR 27.3 million s [ … ]